文献速递肾小球疾病遗传性与小管间质肾病慢性肾脏病

尿液蛋白生物标志物可独立于白蛋白尿和炎症可靠提示Alport综合征儿童极早期肾损伤

Urinary Protein-Biomarkers Reliably Indicate Very Early Kidney Damage in Children With Alport Syndrome Independently of Albuminuria and Inflammation.
PubMed 文献 · Kidney Int Rep · 2023-09-29

该研究通过在AS 0期犬模型中用质谱筛选候选蛋白标志物,并在50例AS患儿和104例健康对照中用ELISA验证。尿液中胶原XIII型、HABP2和C4BP等蛋白单独或联合应用对极早期临床前肾损伤显示出高灵敏度和特异度,且不依赖白蛋白尿和炎症。

要点

  • 尿液胶原XIII型、HABP2和C4BP是提示AS极早期肾损伤的高灵敏度和特异度标志物。
  • 这些尿液标志物可独立于白蛋白尿和炎症反映早期肾损伤。
  • 该标志物组合有望用于AS肾损伤发生前的筛查以实现抢先治疗。

核心结论

  • 尿液蛋白标志物可独立于白蛋白尿和炎症可靠指示Alport综合征儿童的极早期肾损伤。

研究设计与样本

  • 研究先在AS 0期犬模型中用质谱筛选候选蛋白标志物,鉴定出74个候选标志物。
  • 随后用商业ELISA在犬中评估27个标志物,在儿童中评估28个标志物,包括50例AS患儿和104例健康对照。

主要发现

  • 血液标志物多为同一蛋白多种变异体的混合物,ELISA很少检测到疾病特异性变异,故血样差异较小。
  • 尿液中多种蛋白单独或联合应用是极早期临床前肾损伤的有前景指标。
  • 灵敏度和特异度最高的尿液标志物为胶原XIII型、透明质酸结合蛋白2(HABP2)和补体C4结合蛋白(C4BP)。

临床怎么用

  • 这些尿液标志物可能用于Alport综合征肾损伤发生前的筛查,从而允许抢先治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Alport syndrome (AS) is a hereditary type IV collagen disease. It starts shortly after birth, without clinical symptoms, and progresses to end-stage kidney disease early in life. The earlier therapy starts, the more effectively end-stage kidney disease can be delayed. Clearly then, to ensure preemptive therapy, early diagnosis is an essential prerequisite. METHODS: To provide early diagnosis, we searched for protein biomarkers (BMs) by mass spectrometry in dogs with AS stage 0. At this very early stage, we identified 74 candidate BMs. Of these, using commercial enzyme-linked immunosorbent assays (ELISAs), we evaluated 27 in dogs and 28 in children, 50 with AS and 104 healthy controls. RESULTS: Most BMs from blood appeared as fractions of multiple variants of the same protein, as shown by their chromatographic distribution before mass spectrometry. Blood samples showed only minor differences because ELISAs rarely detect disease-specific variants. However, in urine , several proteins, individually or in combination, were promising indicators of very early and preclinical kidney injury. The BMs with the highest sensitivity and specificity were collagen type XIII, hyaluronan binding protein 2 (HABP2), and complement C4 binding protein (C4BP). CONCLUSION: We generated very strong candidate BMs by our approach of first examining preclinical AS in dogs and then validating these BMs in children at early stages of disease. These BMs might serve for screening purposes for AS before the onset of kidney damage and therefore allow preemptive therapy.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Rhode H, Lüse A, Tautkus B, et al. Urinary Protein-Biomarkers Reliably Indicate Very Early Kidney Damage in Children With Alport Syndrome Independently of Albuminuria and Inflammation. Kidney Int Rep. 2023. PMID: 38106579. doi:10.1016/j.ekir.2023.09.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。